The treatment of colorectal carcinoma with monoclonal antibodies - The importance of KRAS mutation analysis and EGFR status;Behandlung des kolorektalen karzinoms mit monoklonalen antikörpern - Bedeutung der KRAS-mutationsanalyse und des EGFR-status

Deutsches Arzteblatt

Volumn 106, Issue 12, 2009, Pages 202-206

  Stintzing, Sebastian ^a   Heinemann, Volker ^a   Jung, Andreas ^b   Moosmann, Nicolas ^a   Hiddemann, Wolfgang ^a   Kirchner, Thomas ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cancer therapy; Cetuximab; Colorectal carcinoma; Gene mutation; Molecular medicine

Indexed keywords

ANTIBIOTIC AGENT; B RAF KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; CORTISONE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; IRINOTECAN; MINOCYCLINE; OXALIPLATIN; PANITUMUMAB; RAS PROTEIN;

ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CYTOTOXICITY; FATIGUE; GENE MUTATION; GENETIC ANALYSIS; HOMEOSTASIS; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; METASTASIS; MUTATIONAL ANALYSIS; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PANCREAS CARCINOMA; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; RASH; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; TREATMENT RESPONSE; WILD TYPE;

ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DRUG DELIVERY SYSTEMS; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MUTATION; PATIENT SELECTION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 68049105287     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2009.0202     Document Type: Review

References (25)

1. Cunningham D et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345 (Pubitemid 38944402)
2. Mayer A et al.: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71: 2454-2460 (Pubitemid 23100476)
3. Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur J Cancer 2001; 37: 9-15.
4. Saltz LB et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208
5. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-2799 (Pubitemid 46606324)
6. Bos JL et al.: Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327: 293-297
7. Finkelstein SD et al.: Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer 1993; 71: 3827-3838
8. Khosravi-Far R and CJ: The Ras signal transduction pathway. Cancer Metastasis Rev 1994; 13: 67-89.
9. Boughdady IS et al.: K-ras gene mutations in adenomas and carcinomas of the colon. Surg Oncol 1992; 1: 275-282
10. Aaltonen LA et al.: Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260: 812-816 (Pubitemid 23167611)
11. Oliveira C et al.: Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 2004; 13: 2303-2311 (Pubitemid 39359927)
12. Bazan V et al.: Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. Ann Oncol 2005; 16: 50-55 (Pubitemid 43084946)
13. Amado RG et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 6: 1626-1634
14. Dietel M et al.: Molecular pathologic KRAS mutation analysis: a prerequisite of effective antibody treatment for metastasized colorectal cancer. Chirurg 2008; 79: 576-579
15. Esteller M et al.: K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 19: 299-304. (Pubitemid 32112840)
16. Andreyev HJ et al.: Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998; 90: 675-684
17. Dix BR et al.: The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 1994; 59: 747-751
18. Karapetis CS et al.: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765
19. Lievre A et al.: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-379 (Pubitemid 351171687)
20. De Roock W et al.: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19: 508-515 (Pubitemid 351325672)
21. Cappuzzo F et al.: Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 2008; 99: 83-89 (Pubitemid 351920237)
22. Di Fiore F et al.: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166-1169 (Pubitemid 46625066)
23. Khambata-Ford S et al.: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-3237 (Pubitemid 47325606)
24. di Nicolantonio F et al.: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712
25. Ince WL et al.: Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005; 97: 981-989